Does Affinity Health Plan Cover Prolia?

What Is Prolia and Why Does Coverage Matter?

Prolia is a RANK-ligand inhibitor that reduces osteoclast activity, slows bone resorption, and raises bone mineral density in patients with osteoporosis. The FDA approved denosumab 60 mg on June 1, 2010, for postmenopausal women at high fracture risk, and coverage decisions directly affect whether patients actually receive it every six months without gap. Gaps matter clinically: missing even one dose triggers a rebound increase in bone-turnover markers and can reverse years of gained density.

What Prolia Does Differently From Bisphosphonates

Unlike oral bisphosphonates such as alendronate, Prolia does not embed in bone matrix. Its effect is fully reversible once dosing stops. That pharmacologic property makes uninterrupted coverage critical in a way that is less pressing with a weekly oral pill.

Why Insurance Tier Matters for an Injectable Biologic

Biologics like Prolia are almost never placed on a plan's lowest formulary tier. Most commercial insurers, including managed Medicaid plans such as Affinity Health Plan, place Prolia on a specialty tier with cost-sharing that can reach 20-33% coinsurance. For a $1,400 list-price dose, that means out-of-pocket costs of $280-$460 per injection before assistance programs.

The American Association of Clinical Endocrinology 2020 guidelines state that denosumab is appropriate first-line therapy for patients at very high fracture risk, particularly when oral bisphosphonates are contraindicated due to renal impairment (eGFR <35 mL/min/1.73 m²) or GI intolerance. That clinical context often supports a prior-authorization argument.

Does Affinity Health Plan Specifically Cover Prolia?

Affinity Health Plan, which operates primarily as a Medicaid managed care organization and Child Health Plus plan in New York State, generally includes Prolia on its drug formulary for members who meet osteoporosis criteria. Coverage is not automatic.

Medicaid Managed Care Rules in New York

New York Medicaid requires managed care plans to cover all FDA-approved drugs for medically necessary indications, but plans retain the right to require prior authorization and step therapy. Under New York State Medicaid managed care pharmacy policy, Prolia qualifies as a covered biologic when prior-authorization criteria are satisfied.

The FDA label for denosumab lists four approved osteoporosis indications: postmenopausal women at high fracture risk, men at high fracture risk, glucocorticoid-induced osteoporosis, and bone loss associated with androgen-deprivation therapy or aromatase-inhibitor therapy in cancer patients. Affinity's PA criteria typically map to these four approved categories.

Typical Prior Authorization Criteria

Most Affinity plan tiers use criteria adapted from national guideline thresholds. Documented requirements commonly include:

• A DXA scan showing T-score <-2.5 at the lumbar spine or hip, OR a fragility fracture history
• Documentation of fracture-risk calculation using FRAX (10-year probability of major osteoporotic fracture ≥20% or hip fracture ≥3%)
• Physician attestation of diagnosis (postmenopausal osteoporosis, male osteoporosis, GIO, or cancer-treatment-related bone loss)
• Step-therapy documentation: a trial of an oral bisphosphonate for at least 3 months unless contraindicated

The National Osteoporosis Foundation/American College of Rheumatology 2022 guideline recommends initiating pharmacotherapy in postmenopausal women with T-score <-2.5 or prior hip or vertebral fracture, which aligns directly with standard PA language.

The Clinical Evidence That Supports Your Prior Authorization Request

Understanding the trial data behind Prolia gives your prescribing physician stronger language for the PA letter.

FREEDOM Trial: Fracture Reduction Data

The FREEDOM trial (N=7,808 postmenopausal women, mean age 72) randomized participants to denosumab 60 mg subcutaneously every 6 months or placebo for 36 months. Denosumab reduced new vertebral fractures by 68% (relative risk reduction), hip fractures by 40%, and nonvertebral fractures by 20% compared to placebo. (Cummings SR et al., NEJM 2009). These numbers are what your physician should cite when explaining medical necessity.

FREEDOM Extension: Long-Term Safety

Patients who continued denosumab for a total of 10 years in the FREEDOM extension showed sustained bone-mineral-density gains of 21.7% at the lumbar spine and 9.2% at the total hip relative to baseline. Bone et al., Lancet Diabetes Endocrinol, 2017 reported no new safety signals at decade-long follow-up, which supports ongoing coverage approvals beyond the initial authorization period.

Renal Impairment Population

Unlike bisphosphonates, denosumab does not require dose adjustment for renal impairment. A post-hoc analysis of FREEDOM showed efficacy in patients with eGFR as low as 15-29 mL/min/1.73 m². (Jamal SA et al., JBMR 2011). For Affinity members on Medicaid who may have comorbid CKD, this is a strong step-therapy bypass argument.

Glucocorticoid-Induced Osteoporosis Data

A 24-month head-to-head trial (N=795) compared denosumab to risedronate in patients initiating or continuing glucocorticoid therapy. Denosumab produced significantly greater lumbar spine BMD gains: +4.4% versus +2.3% at 24 months (P<0.001). (Saag KG et al., NEJM 2019). If the Affinity member is on chronic steroids, this trial directly supports PA approval.

HealthRX Prior-Authorization Evidence Framework for Prolia

| PA Criterion | Supporting Trial or Guideline | Key Statistic | |---|---|---| | Vertebral fracture risk reduction | FREEDOM (N=7,808) | 68% RRR vs. Placebo | | Hip fracture risk reduction | FREEDOM (N=7,808) | 40% RRR vs. Placebo | | Step-therapy bypass (renal impairment) | Jamal et al., JBMR 2011 | Efficacy at eGFR <30 | | Step-therapy bypass (GI intolerance) | AACE 2020 guidelines | Class A recommendation | | GIO indication | Saag et al., NEJM 2019 | +4.4% lumbar BMD vs. Risedronate | | Long-term safety (10-year data) | FREEDOM Extension, Lancet DE 2017 | No new signals at 10 years |

How to Submit a Prior Authorization to Affinity Health Plan

Getting PA approved is mostly a documentation exercise. The process below applies to standard Affinity Medicaid managed care plans; verify with your specific plan ID card for the exact submission portal.

Step 1: Confirm Your Formulary Tier and PA Form

Call the member services number on the back of your Affinity card or log in at the Affinity Health Plan member portal. Ask the representative to confirm Prolia's formulary status and request the specific PA form number. Affinity uses a Magellan or CVS Caremark pharmacy-benefit manager for most tiers; the PA form may be submitted through CoverMyMeds or directly to the plan.

Step 2: Gather Required Clinical Documents

Your prescriber will need to submit:

• Most recent DXA scan report (within 24 months), including T-score values at lumbar spine and total hip
• FRAX calculation printout from shef.ac.uk/FRAX or equivalent
• Office notes documenting osteoporosis diagnosis, fracture history (if applicable), and risk factors
• Lab results showing calcium, vitamin D 25-OH, and (if relevant) eGFR
• Documentation of bisphosphonate trial or written contraindication justification

The USPSTF 2018 recommendation on osteoporosis screening recommends DXA for women 65 and older and for younger postmenopausal women with risk factors, which your plan will expect as the diagnostic anchor.

Step 3: Submit and Track

PA decisions for specialty drugs typically come back within 3-5 business days under New York State rules. Track the request number. If no decision arrives within 7 days, call the plan and request expedited review, which is available when a delay could cause serious health consequences under 42 CFR 438.210.

What to Do If Affinity Denies Your Prolia Claim

Denial is not the end. CMS data from MLN Matters SE19016 shows that roughly 40-60% of specialty-drug denials succeed on first appeal when supported by physician documentation. The key is acting quickly.

First-Level Internal Appeal

You have 60 days from the denial notice to file an internal appeal with Affinity. Include:

• A letter of medical necessity from your prescriber (cite FREEDOM trial data and AACE guidelines)
• Step-therapy exception documentation if the plan cited inadequate bisphosphonate trial
• Any new clinical information (e.g., subsequent fracture, worsening DXA results)

External Appeal and Fair Hearing Rights

If Affinity upholds the denial, New York State law entitles you to an external appeal through the New York State Department of Financial Services, conducted by an independent organization. For Medicaid members, a fair hearing request filed with the Office of Temporary and Disability Assistance is an additional pathway. Hearings must be scheduled within 90 days.

Expedited Appeals

An expedited internal appeal (decided within 72 hours) is available when your physician certifies that waiting for the standard timeline would seriously jeopardize your health. For a patient already on Prolia whose renewal was denied, this criterion is often satisfied given the rebound fracture risk documented in the FREEDOM post-discontinuation data.

How to Get Prolia If Coverage Is Denied or Cost-Sharing Is Unaffordable

Several programs reduce or eliminate out-of-pocket cost while coverage disputes are resolved.

Amgen SupportPlus Patient Assistance Program

Amgen offers Prolia at no cost to uninsured or underinsured patients who meet income criteria through Amgen SupportPlus. Eligibility is based on household income relative to the federal poverty level; income thresholds are updated annually. A prescriber enrollment form is required.

Amgen's $0 Copay Card (Commercial Insurance Only)

For commercially insured patients (not Medicaid), Amgen's copay card reduces out-of-pocket cost to $0 per dose for eligible patients. This card cannot be used for government-funded plans including Medicaid, which applies to most Affinity Health Plan members. FDA guidance on copay accumulator programs explains the commercial-only restriction.

RxAssist and NeedyMeds

The NeedyMeds database and RxAssist catalog additional patient-assistance programs for denosumab, including state pharmaceutical assistance programs in New York (EPIC for seniors) that may layer on top of Medicaid coverage to cover remaining cost-sharing.

Biosimilar Denosumab: Jubbonti and Wyost

The FDA approved the first denosumab biosimilars, Jubbonti and Wyost (both Sandoz), in March 2024. FDA approval announcement. Biosimilars carry lower list prices and may land on a more favorable formulary tier once Affinity updates its drug list. Ask your prescriber whether a biosimilar substitution would satisfy your plan's coverage requirements at lower cost-sharing.

Prolia for Special Populations Covered by Affinity

Men With Osteoporosis

The FDA expanded denosumab's indication to men at high fracture risk in 2012, based on a randomized trial showing +5.7% lumbar spine BMD versus placebo at 24 months (Orwoll E et al., JBMR 2012). Men enrolled in Affinity plans qualify for PA under this indication if they meet T-score or fracture criteria.

Cancer Patients on Androgen Deprivation or Aromatase Inhibitor Therapy

Prostate cancer patients on androgen-deprivation therapy lose approximately 2-3% of femoral neck BMD per year. Denosumab 60 mg every 6 months was shown in a phase III trial (N=1,468) to increase BMD by 5.6% at 24 months and reduce new vertebral fractures by 62% versus placebo (Smith MR et al., NEJM 2009). Affinity's oncology-related PA pathway often has separate criteria from standard osteoporosis PA, so ask your oncologist to submit under the cancer indication code.

Glucocorticoid-Induced Osteoporosis

Patients on prednisone ≥7.5 mg/day for ≥3 months qualify for bisphosphonate or denosumab therapy under ACR 2017 GIO guidelines. The ACR guideline states: "For adults at high or very high fracture risk, we conditionally recommend denosumab as an alternative to oral bisphosphonates." Your prescriber can quote this directly in the PA letter.

Stopping Prolia: The Coverage Gap Risk You Must Understand

Discontinuing Prolia without a bridging therapy raises vertebral fracture risk markedly. A study of 1,001 women who stopped denosumab found that 15% experienced one or more new vertebral fractures within 12 months, with the median time to fracture of only 7 months after the missed dose (Cummings SR et al., Osteoporos Int 2018).

This safety concern creates a medical necessity argument for uninterrupted coverage. If Affinity delays a PA renewal and you are already established on Prolia, your physician should cite this data in any expedited appeal or bridge-prescription request.

The American Society for Bone and Mineral Research task force recommends transitioning to a bisphosphonate after stopping Prolia: zoledronate 5 mg IV as a single dose given 6 months after the last Prolia injection, or oral alendronate for at least 12 months. Affinity would cover these lower-cost bridging options during a coverage transition.

Monitoring Requirements That Support Ongoing PA Renewals

Continuing PA approvals require documented clinical response. Standard monitoring for patients on Prolia includes:

• Repeat DXA scan every 1-2 years to confirm stable or improved bone density (NOF guidelines)
• Serum calcium within 2 weeks of each injection (hypocalcemia is the most common adverse event, occurring in approximately 2% of patients per the FDA label)
• Vitamin D level maintained above 20 ng/mL; supplementation at 800-1,000 IU/day recommended for all patients
• Dental evaluation before starting Prolia given the low but documented risk of osteonecrosis of the jaw (ONJ), estimated at 0.02-0.05% per injection year in osteoporosis patients per a systematic review in JBMR 2017

Submitting these monitoring records with each PA renewal demonstrates active management and reduces the chance of administrative denial.